Advertisement

Picture EBD Group BioPharm America 2021 Digital BPA2021 650x80
Organisation › Details

Sarepta Therapeutics Inc. (NASDAQ: SRPT)

Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including EXONDYS 51, designed to skip exon 51 and approved under the accelerated approval pathway. *

 

Period Start 2016-09-22 existent
Products Industry RNA-based therapeutic
  Industry 2 DRUGS, ORPHAN
Person Person Ingram, Douglas S. (Doug) (Sarepta Therapeutics 201902 CEO)
     
Region Region Cambridge, MA
  Country United States (USA)
  Street 215 First Street
  City 02142 Cambridge, MA
  Tel +1-617-274-4000
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
  Currency USD
  Annual sales 154,584,000 (revenues, total, consolidated (2017) 2017-12-31)
  Profit -50,688,000 (2017-12-31)
  Cash 599,691,000 (2017-12-31)
     
    * Document for �About Section�: SareptaTherapeutics, Inc.. (9/22/16). "Press Release: Sarepta Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock". Cambridge, MA.
     
   
Record changed: 2020-07-08

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Sarepta Therapeutics Inc. (NASDAQ: SRPT)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80




» top